PKE
PARK AEROSPACE CORP
Next earnings Jul 2, 2026 · consensus $0.14 EPS, $18.1M rev
Last earnings +2.4% on 2026-05-28
$33.88
▲ +6.01%$33.88▲ +149.72%
over 1Y
L $13.46EODHDH $36.41
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+6.0%
1W+1.7%
1M-4.8%
3M+23.7%
YTD+60.1%
1Y+149.7%
Buy
Conviction
Horizon
Medium (3–12mo)
Street · 5 analysts
Buy
Revenue grew 18.2% YoY.
Revenue (FY2026) $73.3M · FY2026
The read
The fundamentals carry the rating, but the price is rich (~37% above our fair-value estimate) — a quality-at-a-price call. The case rests on the business, not the entry; patient buyers may wait for a pullback.
PARK AEROSPACE CORP shows $73.3M in FY2026 revenue (+18.2% YoY), a 15.4% net margin, and 8.7% ROE.
Financials · annual, by fiscal year
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | $53.6M | $54.1M | $56.0M | $62.0M | $73.3M |
| Gross profit | $17.9M | $16.5M | $16.5M | $17.6M | $22.7M |
| Operating income | $11.4M | $9.95M | $8.38M | $9.40M | $13.5M |
| Net income | $8.46M | $10.7M | $7.47M | $5.88M | $11.3M |
| Diluted EPS | $0.41 | $0.52 | $0.37 | $0.29 | $0.56 |
| Net margin | 15.8% | 19.9% | 13.3% | 9.5% | 15.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$701M
EV / EBITDA45.6
EV / Sales9.6
EV / FCF74.1
P / FCF74.8
PEG (trailing)0.66
Earnings yield1.6%
FCF yield1.3%
Quality & risk
ROIC (est.)5.3%
Free cash flow$9.46M
Total debt$72.0M
Net cash$6.49M
Altman Z-Score35.79 safe
Piotroski F-Score8/9
Capital returns
Buyback yield0.3%
Dividend yield (est.)1.4%
Shareholder yield1.7%
Shares Δ YoY+5.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- DEF 14A Proxy statement2026-06-22
- 10-K Annual report2026-05-29
- 8-K Earnings results2026-05-28
- 8-K Officer / director change2026-01-16
- 8-K Earnings results2026-01-13
- S-3 Shelf registration (potential raise)2026-01-13
- 10-Q Quarterly report2026-01-13
- 10-Q Quarterly report2025-10-14
- 8-K Earnings results2025-10-09
Recent filings
all on EDGAR ↗DEF 14APeriod ending 2026-07-212026-06-22open ↗4Period ending 2026-06-092026-06-09open ↗10-KPeriod ending 2026-03-012026-05-29open ↗8-KPeriod ending 2026-05-282026-05-28open ↗SCHEDULE 13G/AFiling2026-05-14open ↗SCHEDULE 13G/AFiling2026-03-27open ↗EFFECTFiling2026-01-21open ↗8-KPeriod ending 2026-01-142026-01-16open ↗S-3Filing2026-01-13open ↗10-QPeriod ending 2025-11-302026-01-13open ↗8-KPeriod ending 2026-01-132026-01-13open ↗S-8Filing2026-01-05open ↗
Frequently asked
- Is PARK AEROSPACE CORP (PKE) a buy?
- PKE currently carries a Buy rating with 4/5 conviction, derived from its latest SEC filings. Revenue grew 18.2% YoY.
- What is PKE's fair value?
- A Modified-Graham model based on PKE's SEC fundamentals estimates a fair value of about $21.28. It is an estimate from reported earnings, not a price target.
- Is PKE overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, PKE currently appears overvalued relative to its SEC-grounded earnings power.
- What is PARK AEROSPACE CORP's quality score?
- PKE scores 69.72549019607843/100 (grade B-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000076267, latest 10-K filed 2026-05-29) · EODHD · as of 6/26/2026, 7:06:32 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.